Incurred sample reproducibility: Views and recommendations by the European Bioanalysis Forum

Bioanalysis

Volumn 1, Issue 6, 2009, Pages 1049-1056

  Timmerman, Philip ^a   Luedtke, Silke ^b   Van Amsterdam, Peter ^b   Brudny Kloeppel, Margarete ^c   Lausecker, Berthold ^b   Fischmann, Stephanie ^b   Globig, Susanne ^d   Sennbro, Carl Johan ^b   Jansat, Josep M ^e   Mulder, Hans ^b   Thomas, Elizabeth ^f   Knutsson, Magnus ^g   Kasel, Dirk ^h   White, Stephen A ⁱ   Kall, Morten Anders ^j   Mokrzycki Issartel, Nathalie ^b   Freisleben, Achim ^b   Romero, Fernando ^k   Andersen, Michael Pilgåård ^l   Knebel, Norbert ^b   De Zwart, Marcel ^b   Laakso, Sirpa ^m   Hucker, Richard S ⁿ   Schmidt, Dietmar ^o   Gordon, Ben ^b   Abbott, Richard ^p   Boulanger, Pierre ^q   more..

^a JOHNSON AND JOHNSON   (United States)

^b Boehringer Ingelheim ^*  (Italy)

^c Bayer Schering Pharma AG   (Belgium)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e F Hoffmann La Roche ^*  (Spain)

^f ASTRAZENECA   (United Kingdom)

^g FERRING PHARMACEUTICALS   (United States)

^h GRÜNENTHAL GMBH   (Germany)

ⁱ GLAXOSMITHKLINE   (United States)

^j H LUNDBECK A S   (Denmark)

^k Novartis Pharma AG   (Switzerland)

^l NOVO NORDISK INC   (United States)

^m ORION CORPORATION   (Finland)

ⁿ PFIZER INC   (United States)

^o Sanofi Aventis   (United States)

^p Shire Pharmaceuticals   (United States)

^q UCB PHARMA   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANALYSIS; ARTICLE; EUROPE; HUMAN; PHARMACOKINETICS; PRACTICE GUIDELINE; REPRODUCIBILITY; STANDARD; UNITED STATES;

ANALYTIC SAMPLE PREPARATION METHODS; EUROPE; GUIDELINES AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 77954865192     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.108     Document Type: Article

References (11)

1. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res. 9, 588-592 (1992).
2. Savoie N, Booth BP, Bradley T et al. The 2nd CVG workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis 1(1), 19-30 (2009).
3. Viswanathan CT, Bansal s, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9(1), E30-E42 (2007).
4. Fast DM, Kelley M, Viswanathan C et al. AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of crystal city recommendations. AAPS J. 11(2), 238-241 (2009).
5. US FDA. Guidance for industry bioanalytical method validation. US FDA Center for Drug Evaluation and Research Center for Veterinary Medicine (2001).
6. Rocci ML, Devanarayan V, Haughey DB et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 9(3), E336-E343 (2007).
7. Timmerman P, Lausecker B, Abbott R et al. EBF perspective on experience of incurred sample reanalysis. Presented at: EBF Open Symposium. Barcelona, Spain, 2-4 December 2008.
8. Website Health Canada. Conduct and analysis of bioavailability and bioequivalence studies - part B: oral modified release formulations www.hc-sc.gc.ca/dhp-mps/prodpharma/ applic-demande/guide-ld/bio/bio-b-eng.php
9. Website Health Canada. Notice to industry - removal of requirement for 15% random replicate samples notice affecting guideline A and guideline B requirements www.hc-sc.gc.ca/dhp-mps/prodpharma/ applic-demande/guide-ld/bio/ 15rep-eng.php
10. Garofolo F. The Canadian workshop on the Crystal City AAPS/FDA white paper www.canadianlcmsgroup.com/docs/b
11. Bansal S. Repeat bioanalysis selection and reporting. AAPS Workshop, quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays (2006) www.aapspharmaceutica.com/ meetings/ files/64/bansal.pdf